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mitochondrial area and count in the sPD cohort (p<0.05).
The number and area of lysosomes was increased in sPD
(p<0.05) with 15 sPD patients having a lysosome
count >2 SD higher than the average of controls (>154%),
but CathepsinD/lysosomal activity was decreased. Treatment
with ursodeoxycholic acid (UDCA) improved mitochondrial
function, but not lysosomal impairment in sPD patient tissue
with combined impairment of mitochondrial and lysosomal
function.
Conclusion The detection of distinct pathogenic mechanisms in
individual patients with sPD may help for future disease-
stratification.
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Objective To evaluate patient satisfaction with a nurse-led
new-diagnosis patient pathway for Parkinson’s disease.
Background Receiving a diagnosis of Parkinson’s disease can
result in patients feeling vulnerable and alone. Our patient-led
diagnosis project group has previously identified areas of defi-
ciency and developed and implemented a new nurse-led
patient pathway covering the first year post-diagnosis. In this
project we aimed to evaluate patient experience of this patient
pathway.
Methods A questionnaire was designed to evaluate whether
the pathway was meeting objectives, and delivered to 40
patients diagnosed within the new pathway between March
and September 2016.
Results 19 responses were received (response rate 38.7%).
100% of patients felt they were fully involved in their treat-
ment decisions; 95% felt that treatment was tailored to their
needs; 89% of patients had access to information pre-appoint-
ment and knew to bring a partner; 100% of patients were
given written information during the appointment; 100% of
patients felt supported in their diagnosis; 100% said they
were given a point of contact and 88% of patients eligible for
clinical research were offered the opportunity.
Conclusion Compared with prior to the new pathway, there is
a dramatic increase in patient satisfaction. Cost-effectiveness of
the pathway is currently being evaluated.
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Background The recent discoveries of genes implicated in
striatal dopamine transmission in patients with cervical dysto-
nia have emphasised the central role of the basal ganglia in
the pathogenesis of the condition. Dopamine’s principle role
within the striatum is to bias the action selection function of
the basal ganglia towards the best outcome. Our hypothesis
was that abnormalities of dopamine neurotransmission would
result in a measurable bias in reward based learning in
patients with cervical dystonia.
Methods We used a reversal learning task to assess dopamine
based learning in a group of 40 patients with cervical dystonia
and 40 age matched controls. Exclusion criteria included pre-
vious psychiatric diagnosis or current use of psychotropic
medication.
Results Patients demonstrated a consistent impairment in rever-
sal learning performance compared to controls (15% less
rewards p<0.02) but equivalent pre-reversal reward and loss-
avoidance performance. The contribution from abnormal pre-
diction error signalling are explored using a combination of
computational modelling and fMRI.
Conclusions Patients with cervical dystonia have impaired
reward-reversal learning. Treatments which aim to enhance
reinforcement learning could be explored as future options for
both motor and non-motor symptoms in these patients.
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Vitamin B12 (Cobalamin) deficiency is a well-known cause of
central and peripheral nervous system dysfunction, including
sensorimotor peripheral neuropathy. Methylmalonate CoA
mutase and homocysteine methyltransferase are cobalamin
dependent enzymes. In cobalamin deficiency, the metabolic
reactions catalysed by these enzymes are inhibited, resulting in
the accumulation of methylmalonic acid (MMA) and homocys-
teine in the blood. High plasma levels of MMA and homocys-
teine indicate functional (organic) B12 deficiency in individuals
with normal renal function and normal or low B12 level.
Nitrous oxide (N2O) is a poorly recognised cause of vitamin
B12 deficiency and subsequent neuropathy/myelopathy. We
present a case of 27 year old male who was diagnosed with a
functional (psychogenic) right lower limb focal dystonia. His
severely painful right leg paroxysmal spasms were treated on
more than fifty occasions with Entonox (50:50 n2O and oxy-
gen mixture) over the five years. He developed an axonal sen-
sorimotor neuropathy and was diagnosed with a functional
(organic) B12 deficiency related to N2O administration. His
pre-treatment vitamin B12 levels were normal. However, levels
of MMA and homocysteine were high. He was advised com-
plete cessation of N2O, B12 injections and cognitive behaviou-
ral therapy for the functional limb dystonia. Post-treatment,
his sensory symptoms resolved and MMA and homocysteine
levels normalised.
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